User login
CHICAGO – With new targeted therapies and immunotherapies for metastatic melanoma, chemotherapy is now a thirdtier option for these patients, according to melanoma expert Dr. Lynn M. Schuchter, of the University of Pennsylvania, Philadelphia.
Dr. Schuchter discusses new practice-changing approaches in the treatment of melanoma in an interview at the annual meeting of the American Society of Clinical Oncology.
CHICAGO – With new targeted therapies and immunotherapies for metastatic melanoma, chemotherapy is now a thirdtier option for these patients, according to melanoma expert Dr. Lynn M. Schuchter, of the University of Pennsylvania, Philadelphia.
Dr. Schuchter discusses new practice-changing approaches in the treatment of melanoma in an interview at the annual meeting of the American Society of Clinical Oncology.
CHICAGO – With new targeted therapies and immunotherapies for metastatic melanoma, chemotherapy is now a thirdtier option for these patients, according to melanoma expert Dr. Lynn M. Schuchter, of the University of Pennsylvania, Philadelphia.
Dr. Schuchter discusses new practice-changing approaches in the treatment of melanoma in an interview at the annual meeting of the American Society of Clinical Oncology.
AT THE ASCO ANNUAL MEETING 2013